Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Endocrine Pathology
Published in: Endocrine Pathology 1/2023

09-02-2023 | Hashimoto Thyroiditis

Sclerosing Mucoepidermoid Carcinoma with Eosinophilia of the Thyroid and Mucoepidermoid Carcinoma of the Thyroid: What’s in a Name?

Author: Virginia A. LiVolsi

Published in: Endocrine Pathology | Issue 1/2023

Login to get access

Excerpt

What do sclerosing mucoepidermoid carcinoma with eosinophilia (SMECE) and mucoepidermoid carcinoma of the thyroid (MEC) have in common? They are both primary thyroid carcinomas and they share part of their diagnostic names. Beyond that, similarities are absent (in the opinion of the present author). Unfortunately, the literature on these two entities has led to confusion as to the relationships of the lesions to each other and also, to what is the cell of origin. …
Literature
1.
Le HT, Nguyen TPX, Hirokawa M, et al., Primary thyroid mucoepidermoid carcinoma (MEC) is clinically, prognostically and molecularly different from sclerosing MEC with eosinophilia: A multicenter and integrated study. Endocr Pathol 2022 Nov 17. https://​doi.​org/​10.​1007/​s12022-022-09741-1. Epub ahead of print. PMID: 36394696.
2.
Shah AA, LaFortune K, Miller C, et al. Thyroid sclerosing mucoepidermoid carcinoma with eosinophilia: a clinicopathologic and molecular analysis of a distinct entity. Mod Pathol 2017; 30: 329- 339.CrossRefPubMed
3.
Baloch, ZW Solomon A, LiVolsi VA. Primary mucoepidermoid carcinoma and sclerosing mucoepidermoid carcinoma with eosinophilia of the thyroid gland:A report of nine cases. Mod Pathol. 2000;1 3:802–807.
4.
Baloch ZW, Asa SL, Barletta JA, et al Overview of the 2022 WHO Classification of Thyroid Neoplasms. Endocr Pathol 2022; 33: 27- 63.CrossRefPubMed
5.
Farhat NA, Onenerk AM, Krane J, et al., Primary benign and malignant thyroid neoplasms with signet ring cells, Am J Clin Pathol 2017;148:251-258.CrossRefPubMed
Metadata
Title
Sclerosing Mucoepidermoid Carcinoma with Eosinophilia of the Thyroid and Mucoepidermoid Carcinoma of the Thyroid: What’s in a Name?
Author
Virginia A. LiVolsi
Publication date
09-02-2023
Publisher
Springer US
Published in
Endocrine Pathology / Issue 1/2023
Print ISSN: 1046-3976
Electronic ISSN: 1559-0097
DOI
https://doi.org/10.1007/s12022-023-09754-4

Other articles of this Issue 1/2023

Endocrine Pathology 1/2023 Go to the issue

OriginalPaper

The Presence of Typical “BRAFV600E-Like” Atypia in Papillary Thyroid Carcinoma is Highly Specific for the Presence of the BRAFV600E Mutation

ReviewPaper

Diagnostic, Prognostic, and Predictive Role of Ki67 Proliferative Index in Neuroendocrine and Endocrine Neoplasms: Past, Present, and Future

ReviewPaper

The Impact of the 2022 WHO Classification of Thyroid Neoplasms on Everyday Practice of Cytopathology

OriginalPaper

Primary Thyroid Mucoepidermoid Carcinoma (MEC) Is Clinically, Prognostically, and Molecularly Different from Sclerosing MEC with Eosinophilia: A Multicenter and Integrated Study

ReviewPaper

The Thyroid Pathologist Meets Therapeutic Pharmacology

OriginalPaper

TOP2A Expression in Pheochromocytoma and Abdominal Paraganglioma: a Marker of Poor Clinical Outcome?
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits